Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
Stock Information for Finch Therapeutics Group Inc.
Loading
Please wait while we load your information from QuoteMedia.